H.C. Wainwright Reiterates Buy Rating on iTeos Therapeutics (ITOS)

September 16, 2024 7:13 AM EDT Send to a Friend
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $46.00 price target on iTeos Therapeutics (NASDAQ: ITOS).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login